Nosis Bio

Nosis Bio (Nosis Biosciences) is an AI-native biotech company on a mission to end chronic disease by delivering breakthrough receptor-targeted RNA medicines. The company has built CONNEXA, the first purpose-built platform for receptor-targeted RNA development at scale, combining physics-aware deep learning, single-cell biology, and high-throughput chemistry to design siRNAs and ASOs that silence specific genes in precise cell types across 7 distinct tissues and 11 cell types. Nosis is partnered with Johnson & Johnson and Daiichi Sankyo on cell-targeted RNA programs spanning fibrosis, immunology, inflammation, cardiometabolic disease, and neurology. The company has nominated its first development candidate in fibrosis, demonstrating superior efficacy versus standard-of-care with a clean safety profile at 100x dose. Backed by Madrona Ventures, Nosis operates from a 16,000-square-foot facility in the San Francisco Bay Area.